Webinar | March 25, 2021

Orphan Drugs: Balancing Financial Incentives & Complex Challenges

Source: Thermo Fisher Scientific

Orphan drugs are notorious for their high costs and risk factors, which is attributed to smaller patient pools and higher development and launch costs. Despite the niche, high risk market, orphan drugs are on the rise because of the financial incentives and benefits companies are receiving for new drug development. Whether your orphan drug is a small or large molecule, there are key strategies that you can adopt to enable a seamlessly transition from early development into commercial manufacturing, while also balancing your investment.

Watch this webinar to learn more about:

  • Key trends that are causing the rise of orphan drug indications 
  • Fast tracking early development phases that will lead to commercial success 
  • Navigating a complex regulatory landscape and capacity/resources constraints 
VIEW THE WEBINAR!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Outsourced Pharma? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: